Nanoparticles, anti-inflammatory agents, and reactive oxygen species scavengers
Nanoparticles with crosslinked biocompatible polymers and polyethyleneimine derivatives provide targeted delivery to inflamed areas, enhancing therapeutic efficacy and safety by accumulating in specific regions like the large intestine.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- NAT INST FOR MATERIALS SCI
- Filing Date
- 2022-02-01
- Publication Date
- 2026-06-12
AI Technical Summary
Existing anti-inflammatory agents and ROS scavengers face challenges in safely and effectively delivering to inflamed areas, such as the large intestine, leading to insufficient therapeutic efficacy and systemic side effects.
Nanoparticles composed of crosslinked biocompatible polymers, such as hyaluronic acid or derivatives, crosslinked with polyethyleneimine or its derivatives, with specific molecular weights and amino group contents, designed to have a negative zeta potential and a particle size of 100-1000 nm, allowing targeted delivery to inflamed areas.
The nanoparticles efficiently accumulate in inflamed regions, exhibiting high therapeutic efficacy with reduced systemic side effects and enhanced safety, making them suitable for oral administration.
Smart Images

Figure 0007873470000006 
Figure 0007873470000007 
Figure 0007873470000008